[1] Verseon was founded in 2002 by Adityo Prakash, Eniko Fodor, and David Kita, who created the company's proprietary physics-based computational drug discovery platform.

[2] Through two early rounds of private funding, Verseon raised $34.5 million from high-profile investors including John Leonard, President and Chief Executive Officer of Intellia Therapeutics and former Chief Scientific Officer of AbbVie Inc and Robert Karr former Senior Vice President of R&D Strategy at Pfizer.

[5] Prominent members of Verseon's scientific advisory board include Steven Chu, Nobel Prize-winning physicist and former US energy secretary and Frank Doyle dean of the Harvard John A. Paulson School of Engineering and Applied Sciences.

Nano Magazine noted the platform has produced “multiple chemically diverse clinical candidates…unlikely to be found through any other method” for every one of its drug programs.

[15] Verseon is also conducting a program for the treatment of hereditary angioedema,[16] a rare genetic disorder characterized by recurrent episodes of severe swelling in areas such as the limbs, face, intestinal tract, or airways.